195 related articles for article (PubMed ID: 20701402)
1. Aripiprazole as an augmentation agent in treatment-resistant body dysmorphic disorder.
Uzun O; Ozdemir B
Clin Drug Investig; 2010; 30(10):707-10. PubMed ID: 20701402
[TBL] [Abstract][Full Text] [Related]
2. Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder.
Papakostas GI; Petersen TJ; Kinrys G; Burns AM; Worthington JJ; Alpert JE; Fava M; Nierenberg AA
J Clin Psychiatry; 2005 Oct; 66(10):1326-30. PubMed ID: 16259548
[TBL] [Abstract][Full Text] [Related]
3. Aripiprazole augmentation in 13 patients with refractory obsessive-compulsive disorder: a case series.
Higuma H; Kanehisa M; Maruyama Y; Ishitobi Y; Tanaka Y; Tsuru J; Hanada H; Kodama K; Isogawa K; Akiyoshi J
World J Biol Psychiatry; 2012 Jan; 13(1):14-21. PubMed ID: 22256827
[TBL] [Abstract][Full Text] [Related]
4. A case series of aripiprazole augmentation of selective serotonin reuptake inhibitors in treatment-refractory obsessive compulsive disorder.
Matsunaga H; Hayashida K; Maebayashi K; Mito H; Kiriike N
Int J Psychiatry Clin Pract; 2011 Nov; 15(4):263-9. PubMed ID: 22121999
[TBL] [Abstract][Full Text] [Related]
5. Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 12-week open-label preliminary study.
Pessina E; Albert U; Bogetto F; Maina G
Int Clin Psychopharmacol; 2009 Sep; 24(5):265-9. PubMed ID: 19629012
[TBL] [Abstract][Full Text] [Related]
6. The comparison of aripiprazole and risperidone augmentation in selective serotonin reuptake inhibitor-refractory obsessive-compulsive disorder: a single-blind, randomised study.
Selvi Y; Atli A; Aydin A; Besiroglu L; Ozdemir P; Ozdemir O
Hum Psychopharmacol; 2011 Jan; 26(1):51-7. PubMed ID: 21308781
[TBL] [Abstract][Full Text] [Related]
7. Effect of aripiprazole augmentation for treatment-resistant somatoform disorder: a case series.
Nagoshi Y; Tominaga T; Fukui K
J Clin Psychopharmacol; 2014 Jun; 34(3):397-8. PubMed ID: 24525655
[No Abstract] [Full Text] [Related]
8. An open trial of aripiprazole augmentation for SSRI non-remitters with late-life depression.
Rutherford B; Sneed J; Miyazaki M; Eisenstadt R; Devanand D; Sackeim H; Roose S
Int J Geriatr Psychiatry; 2007 Oct; 22(10):986-91. PubMed ID: 17340654
[TBL] [Abstract][Full Text] [Related]
9. Effects of aripiprazole augmentation in treatment-resistant obsessive-compulsive disorder (a double blind clinical trial).
Sayyah M; Sayyah M; Boostani H; Ghaffari SM; Hoseini A
Depress Anxiety; 2012 Oct; 29(10):850-4. PubMed ID: 22933237
[TBL] [Abstract][Full Text] [Related]
10. Aripiprazole augmentation for a patient with partial remission of panic disorder.
Harada T; Yamada K; Sakamoto K; Ishigooka J
J Clin Psychopharmacol; 2009 Jun; 29(3):301-2. PubMed ID: 19440089
[No Abstract] [Full Text] [Related]
11. Aripiprazole augmentation of clomipramine-refractory obsessive-compulsive disorder.
Friedman S; Abdallah TA; Oumaya M; Rouillon F; Guelfi JD
J Clin Psychiatry; 2007 Jun; 68(6):972-3. PubMed ID: 17592930
[No Abstract] [Full Text] [Related]
12. Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder.
Simon JS; Nemeroff CB
J Clin Psychiatry; 2005 Oct; 66(10):1216-20. PubMed ID: 16259533
[TBL] [Abstract][Full Text] [Related]
13. Chronic catatonia with obsessive compulsive disorder symptoms treated with lorazepam, memantine, aripiprazole, fluvoxamine and neurosurgery.
Mukai Y; Two A; Jean-Baptiste M
BMJ Case Rep; 2011 Aug; 2011():. PubMed ID: 22687661
[TBL] [Abstract][Full Text] [Related]
14. Aripiprazole augmentation in 39 adolescents with medication-resistant obsessive-compulsive disorder.
Masi G; Pfanner C; Millepiedi S; Berloffa S
J Clin Psychopharmacol; 2010 Dec; 30(6):688-93. PubMed ID: 21105283
[TBL] [Abstract][Full Text] [Related]
15. Antipsychotic augmentation of selective serotonin reuptake inhibitors in resistant tic-related obsessive-compulsive disorder in children and adolescents: a naturalistic comparative study.
Masi G; Pfanner C; Brovedani P
J Psychiatr Res; 2013 Aug; 47(8):1007-12. PubMed ID: 23664673
[TBL] [Abstract][Full Text] [Related]
16. Pharmacotherapy in body dysmorphic disorder: relapse prevention and novel treatments.
Dong N; Nezgovorova V; Hong K; Hollander E
Expert Opin Pharmacother; 2019 Jul; 20(10):1211-1219. PubMed ID: 31038370
[No Abstract] [Full Text] [Related]
17. Treatment of residual anxiety symptoms with adjunctive aripiprazole in depressed patients taking selective serotonin reuptake inhibitors.
Adson DE; Kushner MG; Fahnhorst TA
J Affect Disord; 2005 May; 86(1):99-104. PubMed ID: 15820277
[TBL] [Abstract][Full Text] [Related]
18. Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label study.
Clayton AH; Baker RA; Sheehan JJ; Cain ZJ; Forbes RA; Marler SV; Marcus R; Berman RM; Thase ME
BMC Res Notes; 2014 Jul; 7():459. PubMed ID: 25037144
[TBL] [Abstract][Full Text] [Related]
19. Aripiprazole augmentation of venlafaxine in the treatment of psychogenic excoriation.
Carter WG; Shillcutt SD
J Clin Psychiatry; 2006 Aug; 67(8):1311. PubMed ID: 16965218
[No Abstract] [Full Text] [Related]
20. Efficacy and safety of fluvoxamine in body dysmorphic disorder.
Phillips KA; Dwight MM; McElroy SL
J Clin Psychiatry; 1998 Apr; 59(4):165-71. PubMed ID: 9590666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
